1 Markwart, F., “The development of hirudin as an anti-thrombotic drug”, Thromb.
Res., 74, 1—23(1994).
2 Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C.,
Fenton, J.W., “The structure of a complex of recombinant hirudin and human α-thrombin”,
Science, 249, 277—280(1990).
3 Rydel, T.J., Tulinsky, A., Bode, W., Huber, R., “Refined structure of the hirudin
-thrombin complex”, J. Mol. Biol., 221, 583—601(1991).
4 Markwardt, F., “Past, present and future of hirudin”, Haemost. 21(Suppl. 1), 11—
26(1991).
5 Ulbricht, K., Bucha, E., Poschel, KA., Stein, G., Wolf, G., Nowak, G., “The use of
PEG-Hirudin in chronic hemodi-alysis monitored by the Ecarin Clotting Time: Influence on
clotting of the extracorporeal system and hemostatic parameters”, Clin. Nephrol., 65(3),
180—190(2006).
6 Alexander, B., Burnand, K.G., Lattimer, C.L., Humphries, J., Gaffney, P.J.,
Eastham, D., Smith, A., “The effect of anticoagulation with subcutaneously delivered
polyeth-ylene glycol conjugated hirudin and recombinant tissue plasminogen activator on
recurrent stenosis in the rabbit double-balloon injury model”, Thromb. Res., 113(2), 155
—161(2004).
7 Poschel, K.A., Bucha, E., Esslinger, H.U., Ulbricht, K., Nortersheuser, P., Stein,
G., Nowak, G., “Anticoagulant efficacy of PEG-Hirudin in patients on maintenance
hemodialysis”, Kidney Int., 65(2), 666—674(2004).
8 Roberts, M.J., Bentley, M.D., Harris, J.M., “Chemistry for peptide and protein
PEGylation”, Adv. Drug. Deliv. Rev., 54, 459—476(2002).
9 Veronese, F., “Peptide and protein PEGylation: A review of problems and solutions
”, Biomater., 22, 405—417(2001).
10 Monkarsh, S.P., Ma, Y., Aglione, A., Bailon, P., Ciolek, D., DeBarbieri, B.,
Graves, M.C., Hollfelder, K., Michel, H., Palleroni, A., Porter, J.E., Russoman, E., Roy,
S., Pan, Y.E., “Positional isomers of monopegylated interferon a-2a: Isolation,
characterization, and biological activity”, Anal. Biochem., 247, 434—440(1997).
11 Uchio, T., Baudys, M., Liu, F., Song, S.C., Kim, S.W., “Site-specific insulin
conjugates with enhanced stability and extended action profile”, Adv. Drug. Deliv. Rev.,
35, 289—306(1999).
12 Kinstler, O.B., Gabriel, N.E., Farrar, C.E., DePrince, R.B., “N-terminally
chemically modified protein compo-sition methods”, US Pat., 5985265 (1999).
13 Goffin, V., Bernichtein, S., Carriere, O., Bennett, W.F., Kopchick, J.J., Kelly,
P.A., “The human growth hormone antagonist B2036 does not interact with the prolactin re-
ceptor”, Endocrinol., 140, 3853—3856(1999).
14 Giardino, R., Capelli, S., Fini, M., Giavaresi, G., Orienti, L., Veronese, F.M.,
Caliceti, P., Rocca, M., “Biopolymeric modification of superoxide dismutase (mPEG-SOD) to
prevent muscular ischemia-reperfusion damage”, Int. J. Artif. Organs., 18, 167—172(1995).
15 Esslinger, H.U., Haas, S., Mauer, R., Lassmann, A., Dubbers, K., Muler-Pelzer, H.,
“Pharmacolodynamic and safety results of PEG-hirudin in healthy volunteers”, Thromb.
Haemost., 5, 911—919(1997).
16 Li, W.J., Lin, B.C., Su, Z.G., “Analytical methods for PEGylated protein drugs”,
Analysis, 29, 228—231(2001). (in Chinese)
17 Mcgoff, P., Baziotis, A.C., Maskiewicz, R., “Analysis of polyethylene glycol
modified superoxidedismutase by chromatographic, electrophoretic, light scattering,
chemical and enzymatic methods”, Chem. Pharm. Bull., 36, 3079—3091(1988).
18 Biscoff, R., “Polyethylene glycol-hirudin conjugates, process for preparing them
and their use for the treatment of thromboses”, U.S. Pat., 5362858(1994).
19 Snyder, S.L., Sobocinski, P.Z., “An improved 2,4,6-trinitrobenzenesulfonic acid
method for determina-tion of amines”, Anal. Biochem., 64, 284—288(1975).
20 Manfred, M.K., “Detection and molecular weight deter-mination of polyethylene
glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel
electrophoresis”, Anal. Biochem., 200, 244—248(1992).
21 Bullock, J., Chowdhury, S., Severdia, A., Sweeney, J., Johnston, D., Pachla, L., “
Comparison of results of vari-ous methods used to determine the extent of modification of
methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxide dismutase”, Anal.
Biochem., 254, 254—262(1997).
|
京公网安备 11010102001995号
